In Segment C, members will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Participants will receive treatment right until condition progression or perhaps the contributors are not able to tolerate the study drugs. Celastrol was determined as being a Myb inhibitor that suppressed C/EBPβ https://abbv-744preclinicalstudie36790.blogpixi.com/32349021/the-2-minute-rule-for-abbv-744-in-the-treatment-of-drug-resistant-cancers